MYD88 and diffuse large B-cell lymphoma: Additional drugs under development that target NF-κB pathway components upstream of the IKK complex are TLR antagonists and IRAK4 inhibitors, which are potentially interesting for the treatment of DLBCL and WM with MYD88 mutations.